



FOR IMMEDIATE RELEASE

Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces FY 2007 Third Quarter Results

ST. PAUL, MN – May 14, 2007 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the third quarter of fiscal year 2007 ended March 31, 2007.

Revenue for the quarter totaled \$469,151 compared to \$571,988 in the prior year's third quarter ended March 31, 2006, an 18% decrease. The Company incurred a net loss of \$76,948 for the current quarter or \$(.00) per share compared with a net loss of \$276,031 for the prior year's quarter or \$(.01) per share. Included in the net loss of \$76,948 for the quarter are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of \$108,713. The Company reported a cash balance of \$1,431,380 on March 31, 2007.

For the nine month period ended March 31, 2007, total revenue was \$1,440,359, compared to \$1,494,010 for the same period one year ago, a 3.6% decrease. For the nine month period ended March 31, 2007, the Company incurred a net loss of \$490,433, or \$(.01) per share, compared with a net loss of \$897,175, or \$(.03) per share, for the same period one year ago.

"We are pleased with our efforts to decrease expenses which is bringing us close to break-even cash flow," said Mark N. Schwartz, Chairman and CEO.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

– more –

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations (Unaudited)

	Three Months Ended March 31		Nine Months Ended March 31	
	2007	2006	2007	2006
Revenue:				
Equipment sales	\$ 404,800	\$ 457,328	\$ 1,214,606	\$ 1,142,986
Equipment rental	57,955	107,066	198,540	334,210
Service/contract income	6,396	7,594	27,213	16,814
	<u>469,151</u>	<u>571,988</u>	<u>1,440,359</u>	<u>1,494,010</u>
Cost of Sales	13,899	26,471	47,474	88,964
Gross Profit	<u>455,252</u>	<u>545,517</u>	<u>1,392,885</u>	<u>1,405,046</u>
Selling, general and administrative expenses	546,672	831,318	1,933,632	2,332,666
Operating Loss	(91,420)	(285,801)	(540,747)	(927,620)
Other Income (Expense):				
Interest income	14,472	9,770	42,215	30,445
Gain on sale of property and equipment	-	-	8,099	-
Total Other Income	<u>14,472</u>	<u>9,770</u>	<u>50,314</u>	<u>30,445</u>
Net Loss	<u>\$ (76,948)</u>	<u>\$ (276,031)</u>	<u>\$ (490,433)</u>	<u>\$ (897,175)</u>
Basic and Diluted Net Loss per Share	\$ (.00)	\$ (.01)	\$ (.01)	\$ (.03)
Weighted Average Shares Outstanding	39,542,020	35,012,499	39,850,795	33,726,604

Balance Sheet Data

	March 31, 2007 (Unaudited)	June 30, 2006 (Audited)
Cash and cash equivalents	\$ 1,431,380	\$ 1,722,913
Total current assets	1,900,556	2,257,390
Total assets	1,954,174	2,345,949
Total current liabilities	521,602	489,081
Accumulated deficit	(26,468,752)	(25,978,319)
Total shareholders' equity	1,418,371	1,840,414

#

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdii.com